Abstract
The Rac-GEF, P-Rex1, activates Rac1 signaling downstream of G protein-coupled receptors and PI3K. Increased P-Rex1 expression promotes melanoma progression; however, its role in breast cancer is complex, with differing reports of the effect of its expression on disease outcome. To address this we analyzed human databases, undertook gene array expression analysis, and generated unique murine models of P-Rex1 gain or loss of function. Analysis ofPREX1mRNA expression in breast cancer cDNA arrays and a METABRIC cohort revealed that higherPREX1mRNA in ER+ve/luminal tumors was associated with poor outcome in luminal B cancers.Prex1deletion in MMTV-neuor MMTV-PyMTmice reduced Rac1 activation in vivo and improved survival. High level MMTV-driven transgenicPREX1expression resulted in apicobasal polarity defects and increased mammary epithelial cell proliferation associated with hyperplasia and development of de novo mammary tumors. MMTV-PREX1expression in MMTV-neumice increased tumor initiation and enhanced metastasis in vivo, but had no effect on primary tumor growth. Pharmacological inhibition of Rac1 or MEK1/2 reduced P-Rex1-driven tumoroid formation and cell invasion. Therefore, P-Rex1 can act as an oncogene and cooperate with HER2/neu to enhance breast cancer initiation and metastasis, despite having no effect on primary tumor growth.
Funder
Department of Health | National Health and Medical Research Council
Publisher
Proceedings of the National Academy of Sciences
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献